Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 77486.92% year-on-year.
Undervalued
The company’s latest PE is -14.67, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 493.34M shares, decreasing 33.85% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 24.19M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.15.